Weekly Procrit® for Anemia
Procrit is a synthetic form of a natural hormone (erythropoietin) involved in red blood cell production which is approved for treatment of anemia in HIV-infected persons on AZT who have low blood levels of the hormone. This 16-week study will look at whether weekly injections of Procrit can improve quality of life and effectively treat anemia in HIV-infected persons receiving antiretroviral therapy. To be eligible, you must have a hemoglobin of 11 g/dL or below, a low erythropoietin level, and be on stable antiretroviral therapy for at least 4 weeks. Study visits are weekly and participants will be reimbursed $15 at the week 2, 4, 8, 12 and 16 visits.
Ultrase® for Diarrhea
CRIA is participating in a study of Ultrase (pancreatic enzymes) for diarrhea due to the protease inhibitor nelfinavir (Viracept®). The 12-week study, which is being conducted along with CRI New England and CRI South Florida, is open to HIV-infected persons who have been taking nelfinavir at a dose of 1250 mg twice a day for at least two weeks and have three or more stools per day not due to any other cause. Participants will be reimbursed $20 per visit after enrollment.
Protease Inhibitor and Blood Sugar Study
CRIA is conducting a study to examine the effects of protease inhibitor use on responses to the oral glucose tolerance test (measurement of blood sugar levels after taking a drink with a high sugar content). To be eligible, participants must be about to start treatment with a protease inhibitor for the first time. Participants will be reimbursed $30 for each of the first two visits and $50 for the final visit.
Testosterone and MET-RxTMAdvertisementFat Accumulation in the Belly (FAB) Study
CRIA is sponsoring a study of testosterone and MET-Rx, a high protein nutritional supplement for treatment of AIDS-related wasting. Participants will receive testosterone or placebo injections in combination with MET-Rx or a standard nutritional supplement. Participants must be HIV-positive men with T-cell counts of less that 400, low testosterone levels, and weight loss or loss of lean body mass. For information, call Dr. Judith Rabkin at 212-543-5762.
Fat build-up in the abdomen may be a complication of protease inhibitor use. CRIA is conducting a pilot study on the effect of Recombinant Human Growth Hormone (Serostim®) in the treatment of truncal obesity associated with HIV infection. The protocol is examining the safety and efficacy of daily human growth hormone injections over a 24-week period. An extension phase is now being conducted for patients who have completed 24 weeks of therapy to determine longer-term effects. This trial is closed to enrollment.
For more information on any of these studies, please call Dr. Avinash Desai or Dr. Douglas Mendez at (212) 924-3934, or visit our Web site (www.aidsinfonyc.org/cria).
- All material in CRIA Update is presented for educational and informational purposes only, and is not intended as medical advice. All decisions regarding one's personal treatment and therapy choices should be made in consultation with a physician.
- CRIA Update refers to all drugs by both their commercial and scientific names upon their first reference in an article. Thereafter in the article, they will be identified with the name by which we feel they are most commonly known, either commercial or scientific.